Inclusion Criteria:
1. Hyperuricemia patients: Stop uric acid lowering treatment for more than 7 days, and take two non same day treatments within 7 days.Fasting blood uric acid level ≥ 480 μ mol/L;
2. Patients with or without occasional gout: Complies with the 2015 American College of Rheumatology ACR/European Union Against Rheumatism (EULAR) jointly launch diagnosis of gout standardized and screened with less than 2 gout attacks in the previous year;
3. The weight of male subjects is ≥ 50.0kg, and the weight of female subjects is ≥ 45.0kg. Weight refers toBMI is between 18\~30kg/m2, including the critical value
4. The subjects have a good daily routine and are able to maintain good communication and compliance with the researchersAdhere to various requirements of clinical trials;
5. Voluntarily sign the informed consent form.
Exclusion Criteria:
1. Individuals with a history of glucose-6-phosphate dehydrogenase (G6PD) deficiency or abnormal G6PD with clinical significance, history of catalase deficiency, history of autoimmune diseases, and history of atopic allergic diseases;
2. Those with a history of tuberculosis within 6 months before screening;
3. Patients with secondary hyperuricemia;
4. Malignant tumor patients;
5. Organ transplant patients;
6. Individuals with drug allergies;
7. History of acute gout attacks within 2 weeks prior to the screening period or being in the acute gout attack phase at the time of screening;
8. Patients with unstable angina pectoris, serious arrhythmia requiring drug intervention, congestive heart failure \[NYHA rating ≥ Grade II\], uncontrolled hypertension (more than 150/95 mmHg), poor blood glucose control in diabetes patients (i.e. glycosylated hemoglobin HbA1c ≥ 7%), acute stroke, severe or chronic hemorrhagic digestive system disease, pleural effusion, abdominal effusion, etc;
9. Individuals with creatinine levels greater than 1.5 times the upper limit of normal; Individuals with serum transaminase levels exceeding 1.5 times the upper limit of normal range;
10. Individuals who have previously received uricase therapy;
11. Individuals with clear blood system disorders or abnormal coagulation function;
12. Individuals with herpes zoster infection, uncorrected dehydration, acidosis, or currently using nephrotoxic drugs;
13. Virological tests show positive results for HCV antibodies, HIV antibodies, and Treponema pallidum antibodies; HBV: HBsAg and/or HBcAb positive individuals with HBV-DNA above the upper limit of normal values;
14. Individuals with severe mental and psychological disorders, cognitive impairments, and a history of mental illness;
15. Individuals with a tendency to bleed, such as those who experience bleeding or subcutaneous bleeding due to mild collisions during normal times;
16. People who have difficulty with venipuncture, cannot tolerate venipuncture, and have a history of needle and blood dizziness;
17. Those who have undergone surgical procedures within 3 months prior to the first administration, or plan to undergo surgical procedures during the study period;
18. Individuals who have received any other clinical trial drug/device treatment within 3 months prior to the first administration;
19. Those who consume more than 1L of strong tea, coffee, and/or caffeinated beverages per day within the first 3 months prior to the first administration; Eating high purine foods (such as animal organs, seafood, etc.) within 48 hours before administration;
20. Individuals who donate blood or experience significant blood loss (≥ 400mL, excluding normal menstrual blood loss in females), receive blood transfusions, or use blood products within 3 months prior to the first administration of medication;
21. Smoking ≥ 5 cigarettes per day within 3 months before the first administration, or unwilling to ban any tobacco products during the trial period;
22. Positive alcohol breath test results, or those who have been drinking alcohol for more than 14 units per week within the past 3 months before the first administration (1 unit of alcohol equals approximately 285mL of beer, 25mL of strong liquor, or 100mL of wine);
23. Individuals with a history of drug abuse (including repeated and excessive use of various types of narcotics and psychotropic drugs for non-medical purposes) or positive drug abuse screening results within one year prior to the first administration;
24. Individuals who have received inactivated vaccines within one month prior to the first dose, received live/attenuated vaccines within three months prior to the first dose, or plan to receive any vaccines during the trial period;
25. Female subjects who engage in unprotected sexual activity during pregnancy, lactation, or 2 weeks prior to administration, as well as those who have a pregnancy plan or a plan to donate sperm or eggs within 6 months after the end of the trial and are unwilling to use a medically recognized contraceptive method (such as intrauterine devices or condoms) or abstain during the trial period;
26. Those who may not be able to complete this study due to other reasons or who the researcher deems should not be included.